Export

You can select particular sections to be included in the output file.
EN
FR

Model List of Essential Medicines

clear Found 46 recommendations for 36 medicines and 17 therapeutic equivalents
Removed recommendations and rejected applications are shown. Hide them.
18. Medicines for endocrine disorders
  1. Alfacalcidol General information
    Section
    Medicines for endocrine disorders
    • Oral > Liquid: 2 µg per mL
    • Oral > Solid > capsule: 0.25 µg; 1 µg
    Indications
    Chronic kidney disease, stage unspecified Disorders of vitamin D metabolism or transport
  2. Beinaglutide General information
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide for Obesity
  3. Bromocriptine General information
    Section
    Medicines for disorders of the pituitary hormone system
    Indications
    Therapeutic equivalent to cabergoline for Other specified benign neoplasm of endocrine glands
  4. Cabergoline General information
    Section
    Medicines for disorders of the pituitary hormone system
    • Oral > Solid > tablet: 0.5 mg; 1 mg
    Indications
    Other specified benign neoplasm of endocrine glands
  5. Calcitriol General information
    Section
    Medicines for endocrine disorders
    • Oral > Solid > capsule: 0.25 µg; 0.5 µg
    Indications
    Chronic kidney disease, stage unspecified Disorders of vitamin D metabolism or transport
  6. Canagliflozin General information
    Section
    Oral hypoglycaemic agents
    Indications
    Therapeutic equivalent to empagliflozin for Type 2 diabetes mellitus
  7. Carbimazole General information
    Section
    Thyroid hormones and antithyroid medicines
    Indications
    Therapeutic equivalent to methimazole for Thyrotoxicosis
  8. Dapagliflozin General information
    Section
    Oral hypoglycaemic agents
    Indications
    Therapeutic equivalent to empagliflozin for Type 2 diabetes mellitus
  9. Diazoxide General information
    Section
    Medicines for hypoglycaemia
    • Oral > Liquid: 50 mg per mL
    • Oral > Solid: 50 mg
    Indications
    Persistent hyperinsulinaemic hypoglycaemia of infancy
  10. Dulaglutide General information
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide for Obesity Therapeutic equivalent to semaglutide for Type 2 diabetes mellitus
  11. Empagliflozin General information
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 10 mg; 25 mg
    Indications
    Type 2 diabetes mellitus
  12. Estradiol General information
    Section
    Estrogens
    • Oral > Solid > tablet: 0.5 mg; 1 mg; 2 mg
    Indications
    Gonadotropin deficiency Hypopituitarism Turner syndrome
  13. Exenatide General information
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide for Obesity
  14. Fludrocortisone General information
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Liquid: 100 µg per mL
    • Oral > Solid > tablet: 100 µg (acetate)
    Indications
    Adrenocortical insufficiency
  15. Glibenclamide General information
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 5 mg; 2.5 mg
    Indications
    Type 2 diabetes mellitus
  16. Gliclazide General information
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release
    Indications
    Type 2 diabetes mellitus
  17. Glucagon General information
    Section
    Medicines for hypoglycaemia
    • Parenteral > General injections > unspecified: 1 mg per mL as powder and diluent
    Indications
    Hypoglycaemia in the context of diabetes
  18. Hydrocortisone General information
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid > tablet: 5 mg; 10 mg; 20 mg
    • Oral > Solid > granules: 0.5 mg in capsule; 1 mg in capsule; 2 mg in capsule; 5 mg in capsule
    Indications
    Adrenocortical insufficiency
  19. Insulin (analogue, long-acting) General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution; 100 IU per mL in 10 mL vial solution
    Indications
    Type 2 diabetes mellitus Type 1 diabetes mellitus
  20. Insulin (analogue, rapid-acting) General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per 1 mL in 10 mL vial; 100 IU per 1 mL in 3 mL cartridge; 100 IU per 1 mL in 3 mL pre-filled pen
    Indications
    Type 1 diabetes mellitus Type 2 diabetes mellitus
  21. Insulin (human, intermediate-acting) General information
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin
    Indications
    Type 2 diabetes mellitus Type 1 diabetes mellitus
  22. Insulin (human, short-acting) General information
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial solution; 100 IU per mL in 10 mL vial solution; 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution
    Indications
    Type 2 diabetes mellitus Type 1 diabetes mellitus
  23. Insulin analogues General information
    Section
    Insulins
    • Not specified
    Indications
    Type 1 diabetes mellitus Type 2 diabetes mellitus
  24. Insulin aspart General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 110 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
    • Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
    Indications
    Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 2 diabetes mellitus
  25. Insulin degludec General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 units per mL
    Indications
    Therapeutic equivalent to insulin glargine for Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 1 diabetes mellitus
  26. Insulin detemir General information
    Section
    Insulins
    Indications
    Therapeutic equivalent to insulin glargine for Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 1 diabetes mellitus
  27. Insulin glargine General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 units per mL
    Indications
    Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 1 diabetes mellitus
  28. Insulin glulisine General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
    Indications
    Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 2 diabetes mellitus
  29. Insulin lispro General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
    Indications
    Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 1 diabetes mellitus Therapeutic equivalent to insulin (analogue, rapid-acting) for Type 2 diabetes mellitus
  30. Iodine + potassium iodide (Lugol's solution) General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Liquid: 5% w/v + 10% w/v (aqueous)
    Indications
    Thyrotoxicosis
  31. Ketoconazole General information
    Section
    Medicines for endocrine disorders
    • Oral > Solid > tablet: 200 mg
    Indications
    Cushing syndrome
  32. Levothyroxine General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)
    Indications
    Hypothyroidism
  33. Liraglutide General information
    Section
    Medicines for endocrine disorders
    • Parenteral > General injections > SC: 6 mg per mL in 3 mL pre-filled pen
    Indications
    Obesity
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide for Obesity Therapeutic equivalent to semaglutide for Type 2 diabetes mellitus
  34. Medroxyprogesterone acetate General information
    Section
    Progestogens
    • Oral > Solid: 5 mg
    Indications
    Excessive menstruation with irregular cycle
  35. Metformin General information
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 500 mg (hydrochloride)
    Indications
    Type 2 diabetes mellitus
  36. Methimazole General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid > tablet: 5 mg; 10 mg
    Indications
    Thyrotoxicosis
  37. Norethisterone General information
    Section
    Progestogens
    • Oral > Solid: 5 mg
    Indications
    Excessive menstruation with irregular cycle Therapeutic equivalent to medroxyprogesterone acetate for Excessive menstruation with irregular cycle
  38. Octreotide General information
    Section
    Medicines for disorders of the pituitary hormone system
    • Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent
    • Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate)
    Indications
    Acromegaly or pituitary gigantism
  39. Phosphorus General information
    Section
    Medicines for endocrine disorders
    • Oral > Other: 500 mg in sachet (elemental phosphorus) granules
    • Oral > Solid > tablet: 250 mg (elemental phosphorus); 500 mg (elemental phosphorus); 500 mg (elemental phosphorus) (effervescent)
    Indications
    Hypophosphataemic rickets
  40. Potassium iodide General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid > tablet: 65 mg (scored)
    Indications
    Thyrotoxicosis
  41. Prednisolone General information
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid > tablet: 1 mg
    Indications
    Adrenocortical insufficiency
  42. Prednisone General information
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid > tablet: 1 mg
    Indications
    Therapeutic equivalent to prednisolone for Adrenocortical insufficiency
  43. Propylthiouracil General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 50 mg
    Indications
    Thyrotoxicosis
  44. Semaglutide General information
    Section
    Hypoglycaemic agents
    • Parenteral > General injections > SC: 0.25 mg in pre-filled pen injection solution; 0.5 mg in pre-filled pen injection solution; 1 mg in pre-filled pen injection solution; 2 mg in pre-filled pen injection solution; 4 mg in pre-filled pen injection solution
    • Oral > Solid > tablet: 3 mg
    • Parenteral > General injections > SC: 0.68 mg per mL; 1.34 mg per mL; 2.68 mg per mL
    Indications
    Obesity Type 2 diabetes mellitus
  45. Simvastatin General information
    Section
    Medicines for endocrine disorders
    • Oral > Solid: 20 mg
    Indications
    Polycystic ovary syndrome
  46. Somatropin General information
    Section
    Medicines for endocrine disorders
    • Parenteral > General injections > SC: 5 mg in cartridge powder for injection; 5 mg per mL in 2 mL cartridge
    Indications
    Hypoglycaemia without associated diabetes
  47. Testosterone General information
    Section
    Androgens
    • Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)
    Indications
    Testicular dysfunction or testosterone-related disorders
  48. Tirzepatide General information
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide for Obesity Therapeutic equivalent to semaglutide for Type 2 diabetes mellitus
  49. Tolbutamide General information
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 500 mg
    Indications
    Type 2 diabetes mellitus
  50. Zoledronic acid General information
    Section
    Medicines for endocrine disorders
    • Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle
    Indications
    Osteogenesis imperfecta